Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02159638
• Other study ID #: VGFOUREG-387191
• Status: Completed
• Phase: N/A
• First received: June 5, 2014
• Last updated: December 18, 2017
• Start date: May 2013
• Est. completion date: September 1, 2014

Study information

• Verified date: June 2014
• Source: Vastra Gotaland Region
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Continuous glucose monitoring (CGM) is a tool used in the treatment of patients with type 1 diabetes. A continuous glucose monitor (CGM) is a subcutaneous tissue sensor, which provides a tissue fluid glucose measurement every 1 to 5 minutes. Since CGM measure the glucose level by a sensor in subcutaneous tissue, there is uncertainty in the estimation of blood glucose levels. The accuracy of a certain CGM system can be assessed by comparing the glucose levels estimated by CGM with measured glucose levels in plasma. In the current study, we will compare the accuracy of the 2 CGM systems available on the market for clinical use in patients with type 1 diabetes. The aim of the current study is to evaluate effectiveness, safety and treatment satisfaction with 2 different CGM systems among adult type 1 diabetic patients.

Description:

Each study patient will have both subcutaneous tissue CGM sensors inserted. Each sensor will produce a maximum of 1,440 tissue fluid glucose measurements per 24 hours and 8,460 measurements during the 6 days in study. The plan is to study 36 to 50 ambulatory patients during the hole study period. The two CGM data sets (DexCom4G and Medtronic Enlite) will be compared to each other and the time-matched reference blood glucose measurements.

The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose.

Each ambulatory patient will sample capillary blood and measure the concentration of glucose 6 to 10 times per day for max 6 days. The concentration of finger-stick capillary blood glucose will be measured using the HemoCue meter in their daily living and additionally a HemoCue Analyser at research visits using a lancet. Each patient will be admitted to the clinical research unit (CRU) for 7 measurements of venous samples at two occasions: on day 1-3 and 4-6 of the study with an interval of at least 15 minutes. An intravenous catheter will be inserted to facilitate blood sample acquisition each of these days of study. Three capillary finger-stick blood will be sampled at these 2 occasions, 1 at the first venous measurement (one day of days 1-3) and one at the last venous sample (one day of days 4-6).

Blood sample acquisition and handling will be standardized to minimize pre-analytical error.

The sensor insertion sites will be observed to detect bleeding, inflammation and infection of the skin or subcutaneous tissue. Insertion sites will be photographed if any abnormal findings exist at the end of the study for the individual patient.

The subjects will record self monitoring of blood glucose (SMBG), meal, and activity data in a written diary.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: September 1, 2014
• Est. primary completion date: July 1, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Type 1 diabetes

2. Adult patients, age 18 or older and <75 years.

3. Written Informed Consent

Exclusion Criteria:

1. Pregnancy

2. Patients with severe cognitive dysfunction or other disease which makes CGM use difficult.

3. Patients requiring continuous use of paracetamol. Paracetamol must not have been used

the week before the study and shall not be used during the duration because it disturbs the

interpretation of blood glucose levels estimated by the DexCom4G. However, other pain

killers can be used throughout the study period.

4. Current CGM use

5. History of allergic reaction to any of the CGMS materials

or adhesives in contact with the skin.

6. History of allergic reaction to chlorhexidine or alcohol

anti-septic solution.

7. Abnormal skin at the anticipated glucose sensor

attachment sites (excessive hair, burn, inflammation,

infection, rash, and/or tattoo).

Related Conditions & MeSH terms

• Blood Glucose
• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Device:
• Guardian Enlite sensor
Sensor insertion
• Dexcom G4 platinum sensor
Sensor insertion

Locations

Country	Name	City	State
Sweden	NU-hospital Organisation	Trollhattan
Sweden	Uddevalla hospital	Uddevalla

Sponsors (1)

Lead Sponsor	Collaborator
Vastra Gotaland Region

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference between the two CGM systems compared to capillary glucose value	Primary efficacy analysis will be investigating whether there is a statistically significant difference between the two CGM systems with respect to mean absolute relative difference (MARD) of estimated capillary glucose value over the whole study period.	6 days
Secondary	the accuracy of the 2 CGM systems during each studied time interval (day 1-3 and day 4-6)	Accuracy of all estimated capillary glucose values (registered both during days 1-3 and days 4-6) of DexCom 4G system (DexCom sensor) vs Guardian Real-Time system (Enlite sensor) system compared to the capillary reference blood glucose measured with HemoCue.	day 1-3 and day 4-6
Secondary	the accuracy of the 2 CGM systems for hypoglycaemia	Accuracy in estimating capillary glucose levels <4 registered both during days 1-3 and days 4-6 of DexCom 4G system (DexCom sensor) vs Guardian Real-Time system (Enlite sensor) system compared to the capillary reference blood glucose measured with HemoCue(hypo, normoglycaemia and hyperglycaemia)	6 days
Secondary	the accuracy of the 2 CGM systems for normoglycaemia	Accuracy in estimating capillary glucose levels of 4.0-10.0 mmol/l registered both during days 1-3 and days 4-6 of DexCom 4G system (DexCom sensor) vs Guardian Real-Time system (Enlite sensor) system compared to the capillary reference blood glucose measured with HemoCue	6 days
Secondary	the accuracy of the 2 CGM systems for hyperglycaemia	Accuracy in estimating capillary glucose levels >14.0 mmol/l registered both during days 1-3 and days 4-6 of DexCom 4G system (DexCom sensor) vs Guardian Real-Time system (Enlite sensor) system compared to the capillary reference blood glucose measured with HemoCue	6 days
Secondary	Evaluation of two CGM systems from questionnaire	Evaluation of DexCom 4G system (DexCom sensor) vs Guardian Real-Time system (Enlite sensor) from questionnaire	day 6